Body of work: Long-awaited IPO nears for promising biotech firm

From surgical training to high school dissection labs, SynDaver has charted a clear-cut course for its synthetic human and animal products. A payoff for investors could be in the offing.

Mark Wemple. Over the past 15 years, SynDaver founder and CEO Dr. Christoper Sakezles has guided the biotech firm to the brink of what could be a lucrative IPO.
Mark Wemple. Over the past 15 years, SynDaver founder and CEO Dr. Christoper Sakezles has guided the biotech firm to the brink of what could be a lucrative IPO.
  • Strategies
  • Share

SynDaver, the Tampa biotech firm that makes incredibly lifelike artificial humans and animals — most recently a fake frog used in biology class dissections — has long talked of going public. More than four years ago, 2018 was touted as the year Wall Street would welcome it to the party.

 

Continue reading your article
with a Business Observer subscription.
What's included:
  • ✓ Unlimited digital access to BusinessObserverFL.com
  • ✓ E-Newspaper app, digital replica of print edition
  • ✓ Mailed print newspaper every Friday (optional)
  • ✓ Newsletter of daily business news
Subscribe

Already subscribed? Sign in.

Latest News

  • April 1, 2026
Work starts on Naples apartments as developer secures $45M in financing
  • April 1, 2026
$300K Bradenton EDC contract up for vote in Manatee
  • April 1, 2026
27 Gulf Coast companies ranked among fastest growing in Southeast
  • April 1, 2026
Tampa tire store franchisor rolls into new brands, buys a restaurant

Sponsored Content